Affimed NV (Affimed NV) Common Stock : $1.64 Mil (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Affimed NV Common Stock?

Affimed NV's quarterly common stock declined from Jun. 2023 ($1.62 Mil) to Sep. 2023 ($1.59 Mil) but then increased from Sep. 2023 ($1.59 Mil) to Dec. 2023 ($1.64 Mil).

Affimed NV's annual common stock increased from Dec. 2021 ($1.39 Mil) to Dec. 2022 ($1.58 Mil) and increased from Dec. 2022 ($1.58 Mil) to Dec. 2023 ($1.64 Mil).

Affimed NV Common Stock Historical Data

The historical data trend for Affimed NV's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Affimed NV Common Stock Chart

Affimed NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

0.85

1.20

1.39

1.58

1.64

Affimed NV Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Common Stock	Get a 7-Day Free Trial															1.58	1.60	1.62	1.59	1.64

Affimed NV Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Affimed NV (Affimed NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affimed NV (NAS:AFMD) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

A28:Germany

Address

Im Neuenheimer Feld 582, Technologiepark, Heidelberg, BW, DEU, 69120

Website

https://www.affimed.com

Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. The company is also developing single and combination therapies to treat cancers and other life-threatening diseases. Geographically, it derives a majority of revenue from the United States and also has a presence in Europe and Germany.